BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  US Device


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


NovaBay Pharmaceuticals, Inc. 

5980 Horton Street
Suite 550
Emeryville  California  94608  U.S.A.
Phone: 510-899-8800 Fax: 510-779-5468


View Clinical Trials from BioPharm Insight

NovaBay Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with its two distinct categories of products: Aganocide® compounds and NeutroPhase®. Aganocide compounds, led by NVC-422, are patented, synthetic molecules with a broad spectrum of activity against bacteria, viruses and fungi. Mimicking the mechanism of action that human white blood cells use against infections, Aganocides possess a very low likelihood that bacteria or viruses will be able to develop resistance, which is critical for advanced anti-infectives. Having demonstrated clinical efficacy in Phase 2 proof-of-concept clinical studies, NVC-422 is suited to treat and prevent a wide range of local, non-systemic infections. NovaBay’s clinical development activities are focused on three disease areas: Dermatology, Ophthalmology and Urology.

NovaBay has entered into a licensing and research collaboration agreement with Galderma S.A., a global leading pharmaceutical company dedicated exclusively to the field of dermatology. NovaBay is also developing NeutroPhase, which is an FDA 510(k)-cleared product for advanced wound care. NovaBay believes that NeutroPhase is the only patented pure hypochlorous acid solution available which has the potential to be best suited to treat the six-million-patients in the U.S. who suffer from chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers.

 Key Statistics

Ownership: Public

Web Site: NovaBay Pharmaceuticals, Inc.
Symbol: NBY

 Company News
Woundsource Reports On The Role Of NovaBay Pharmaceuticals, Inc. (NBY)’s Neutrophase® In Treatment Of ‘Flesh-Eating’ Infections 4/17/2014 9:50:34 AM    More...
NovaBay Pharmaceuticals, Inc. (NBY) Announces Pricing Of Public Offering Of Common Stock And Warrants 3/20/2014 8:54:28 AM    More...
NovaBay Pharmaceuticals, Inc. (NBY) CEO Comments On President Obama's 'Superbug' Budget Initiative And Reports By The Centers for Disease Control and Prevention (CDC) On Antibiotic Resistance 3/7/2014 8:56:52 AM    More...
NovaBay Pharmaceuticals, Inc. (NBY) Reports Fourth Quarter 2013 and 2013 Year End Financial Results and Provides a Clinical/Business Update 3/7/2014 8:40:05 AM    More...
NovaBay Pharmaceuticals, Inc. (NBY) Grants Principle Business Enterprises Exclusive Marketing And Distribution Rights In The US For Neutrophase®, An Advanced Wound And Skin Cleanser 2/26/2014 9:06:50 AM    More...
NovaBay Pharmaceuticals, Inc. (NBY)'s Neutrophase® Is Best In Class In Laboratory Study Of 19 Top Commercial Wound Cleansers 2/18/2014 9:33:09 AM    More...
NovaBay Pharmaceuticals, Inc. (NBY)'s Neutrophase® Is Best In Class In Laboratory Study Of 19 Top Commercial Wound Cleansers 2/17/2014 8:39:13 AM    More...
NovaBay Pharmaceuticals, Inc. (NBY) To Present At The Annual Dialysis Conference In Atlanta 2/7/2014 9:22:24 AM    More...
Dr. John Crew Gives Grand Rounds Presentation On Treating Wounds With NovaBay Pharmaceuticals, Inc. (NBY)'s Neutrophase At Eisenhower Medical Center 2/6/2014 9:36:02 AM    More...
NovaBay Pharmaceuticals, Inc. (NBY) To Present At Biotechnology Industry Organization (BIO) CEO & Investor Conference 2/3/2014 8:42:33 AM    More...